Integra Lifesciences Holdings Corp (IART) 50.26 $IART
Italy Tissue Engineered - Skin Substitutes Market Outlook to 2020: Key players covered include Organogenesis, Smith & Nephew and Molnlycke Health Care
M2 - Wed Dec 10, 11:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/gzsh2g/italy_tissue) has announced the addition of the "Italy Tissue Engineered - Skin Substitutes Market Outlook to 2020" report to their offering. Our new report, "Italy Tissue Engineered - Skin Substitutes Market Outlook to 2020", provides key market data on the Italy Tissue Engineered - Skin Substitutes market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments - Synthetic Skin Substitutes, Biosynthetic Skin Substitutes and Biologic Skin Substitutes (Allograft (Cellular and Acellular) and Xenograft Acellular). The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Tissue Engineered - Skin Substitutes market wherever available. The data in the report is derived from dynamic market forecast models. The publisher uses epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible. The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers. Key Topics Covered: 1 List of Tables 2 Introduction 3 Tissue Engineered - Skin Substitutes Market, Italy 4 Overview of Key Companies in Italy, Tissue Engineered - Skin Substitutes Market 5 Appendix Companies Mentioned: - Organogenesis, Inc. - Molnlycke Health Care AB - Smith & Nephew Plc - BSN medical GmbH - Integra LifeSciences Holdings Corporation - Kinetic Concepts, Inc. - Covidien plc For more information visit http://www.researchandmarkets.com/research/gz...aly_tissue
SNN: 32.48 (-0.41), IART: 50.26 (-0.15)
Asia-Pacific Tissue Engineered - Skin Substitutes Market Outlook to 2020: Key players covered include Japan Tissue Engineering and Smith & Nephew
M2 - Tue Dec 09, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/ctmnfq/asiapacific) has announced the addition of the "Asia-Pacific Tissue Engineered - Skin Substitutes Market Outlook to 2020" report to their offering. Our new report, "Asia-Pacific Tissue Engineered - Skin Substitutes Market Outlook to 2020", provides key market data on the Asia-Pacific Tissue Engineered - Skin Substitutes market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments - Synthetic Skin Substitutes, Biosynthetic Skin Substitutes and Biologic Skin Substitutes (Allograft (Cellular and Acellular) and Xenograft Acellular). The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Tissue Engineered - Skin Substitutes market wherever available. The data in the report is derived from dynamic market forecast models. The publisher uses epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible. Key Topics Covered: 1 List of Tables 2 Introduction 3 Tissue Engineered - Skin Substitutes Market, Asia-Pacific 4 Tissue Engineered - Skin Substitutes Market, Australia 5 Tissue Engineered - Skin Substitutes Market, China 6 Tissue Engineered - Skin Substitutes Market, India 7 Tissue Engineered - Skin Substitutes Market, Japan 8 Tissue Engineered - Skin Substitutes Market, South Korea 9 Overview of Key Companies in Asia-Pacific Tissue Engineered - Skin Substitutes Market 10 Appendix Companies Mentioned: - Japan Tissue Engineering Co., Ltd. - Smith & Nephew Plc - PolyNovo Biomaterials Pty Ltd - Molnlycke Health Care AB - National Tissue Engineering Research Center - L&C Bio - BSN medical GmbH - Covidien plc - Kinetic Concepts, Inc. - CG Bio Inc. - Integra LifeSciences Holdings Corporation - HansBiomed Co., Ltd - Cellumed Co. Ltd For more information visit http://www.researchandmarkets.com/research/ct...siapacific
SNN: 32.48 (-0.41), IART: 50.26 (-0.15)
Symmetry Medical Divests OEM, Surgical Goes Public - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 12:40PM CST
Symmetry Medical Inc. (SMA) recently completed the divestiture of its OEM solutions business unit to Tecomet Inc.
SMA: 9.27 (-0.04), IART: 50.26 (-0.15), MDT: 72.52 (-1.25), CFN: 58.86 (-0.14)
Integra LifeSciences Earnings Review: 14 Days after Announcement Shares Down 7.5% (IART)
Comtex SmarTrend(R) - Mon Nov 17, 3:46PM CST
14 days ago, on November 3rd, 2014, Integra LifeSciences (NASDAQ:IART) reported its earnings. Analysts, on average, expected earnings of $0.74 per share on sales of $233.7 million. Integra LifeSciences actually reported earnings of $0.76 per share on sales of $229.7 million, beating EPS estimates by $0.02 and missing revenue estimates by $3.9 million. Since the company's report, shares of Integra LifeSciences have fallen from $51.49 to $47.64, representing a loss of 7.5% in the past 14 days.
IART: 50.26 (-0.15)
Integra (IART) Strengthens Spinal Implant with Twin Launches - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 2:30PM CST
The latest Interbody and orthobiologic device launches are expected to drive a sequential increase in Integra Lifesciences' (IART) spine sales in the fourth quarter of 2014.
IART: 50.26 (-0.15), ANIP: 54.28 (+2.33), AMAG: 40.04 (-0.79), AFFX: 8.94 (-0.36)
Update: Integra LifeSciences - A Buy After Q3 2014 Earnings
Andy Batts - at Seeking Alpha - Fri Nov 14, 8:23AM CST
IART: 50.26 (-0.15)
Integra LifeSciences wins FDA clearance and controlled market release for Integra Expandable Interbody System in the US
M2 - Fri Nov 14, 6:59AM CST
Medical technology company Integra LifeSciences Holdings (NasdaqGS:IART) said on Thursday that it has received the controlled market release of the Integra Expandable Interbody System in the US.
IART: 50.26 (-0.15)
Integra LifeSciences Announces FDA Clearance and Controlled Market Release of Expandable Interbody System for Spinal Surgery
GlobeNewswire - Thu Nov 13, 7:30AM CST
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the controlled market release of the Integra Expandable Interbody System, in the United States. The system, which received 510(k) clearance from the United States Food and Drug Administration (FDA) earlier this year, is intended for spinal fusion procedures at one or two contiguous levels (L2-S1) in skeletally mature patients with degenerative disc disease (DDD). The device is intended for use with autogenous bone graft and supplemental fixation and can be used in either posterior or transforaminal lumbar interbody fusion procedures. These procedures are performed to help alleviate pain and nerve compression by fusing and stabilizing adjacent vertebrae in the lower back.
IART: 50.26 (-0.15)
North America Tissue Engineered Skin Substitutes Market Outlook to 2020: Key Players Organogenesis, Inc, Kinetic Concepts, Inc., Shire Plc & Smith & Nephew Plc.
M2 - Thu Nov 13, 3:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/8vj74f/north_america) has announced the addition of the "North America Tissue Engineered - Skin Substitutes Market Outlook to 2020" report to their offering. "North America Tissue Engineered - Skin Substitutes Market Outlook to 2020", provides key market data on the North America Tissue Engineered - Skin Substitutes market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments - Synthetic Skin Substitutes, Biosynthetic Skin Substitutes and Biologic Skin Substitutes (Allograft (Cellular and Acellular) and Xenograft Acellular). The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Tissue Engineered - Skin Substitutes market wherever available. The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers. Capital equipment-based forecasting models are done based on the installed base, replacements and new sales of a specific device/equipment in healthcare facilities such as hospitals, clinics and diagnostic centers. Data for average number of units per facility is used to arrive at the installed base of the capital equipment. Sales for a particular year are arrived at by calculating the replacement units and new units (additional and first-time purchases). Scope - Annualized market revenues (USD million), volume (units) and average prices (in US dollars) data for each of the market segments. Data is provided from 2005 to 2013 and forecast to 2020. - 2013 company shares and distribution shares data for Tissue Engineered - Skin Substitutes market. - Global corporate-level profiles of key companies operating within the North America Tissue Engineered - Skin Substitutes. Companies Mentioned - Organogenesis, Inc. - Shire Plc - Kinetic Concepts, Inc. - Integra LifeSciences Holdings Corporation - Smith & Nephew Plc - Covidien plc - Molnlycke Health Care AB - BSN medical GmbH For more information visit http://www.researchandmarkets.com/research/8v...th_america
SNN: 32.48 (-0.41), IART: 50.26 (-0.15), SHPG: 213.70 (-0.41)
Integra LifeSciences Introduces Integra(R) Pocket Strip and Integra(R) Shaped Strip DBM Implants
GlobeNewswire - Wed Nov 12, 7:54AM CST
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the limited market release of a new orthobiologic implant. The Demineralized Bone Matrix (DBM) Strip implant is used primarily for posterior lumbar fusion, a surgical procedure intended to promote bone fusion along the posterior elements of the spine. Integra's newest orthobiologic implant, distributed by Integra's subsidiary IsoTis OrthoBiologics, will be featured at the North American Spine Society (NASS) 29 annual meeting, November 12 - 15, 2014 in San Francisco, California.
IART: 50.26 (-0.15)
BRIC Tissue Engineered - Skin Substitutes Market Outlook to 2020: Key Players are Japan Tissue Engineering Co., Ltd. and Smith & Nephew Plc
M2 - Wed Nov 12, 5:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/scwv2r/bric_tissue) has announced the addition of the "BRIC Tissue Engineered - Skin Substitutes Market Outlook to 2020" report to their offering. The report provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Tissue Engineered - Skin Substitutes market wherever available. The data in the report is derived from dynamic market forecast models. The publisher uses epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible. The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers. Skin Substitutes market. - Synthetic Skin Substitutes - Biosynthetic Skin Substitutes and Biologic - Skin Substitutes (Allograft (Cellular and Acellular) and Xenograft Acellular). Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Tissue Engineered - Skin Substitutes Market, BRIC 4 Tissue Engineered - Skin Substitutes Market, Brazil 5 Tissue Engineered - Skin Substitutes Market, Russia 6 Tissue Engineered - Skin Substitutes Market, India 7 Tissue Engineered - Skin Substitutes Market, China 8 Overview of Key Companies in BRIC Tissue Engineered - Skin Substitutes Market 9 Appendix Companies Mentioned - National Tissue Engineering Research Center - Organogenesis, Inc. - Kinetic Concepts, Inc. - Smith & Nephew Plc - Integra LifeSciences Holdings Corporation - Eucare Pharmaceuticals (P) Ltd. - MedSkin Solutions Dr. Suwelack AG - Molnlycke Health Care AB - BSN medical GmbH - Covidien plc For more information visit http://www.researchandmarkets.com/research/sc...ric_tissue
SNN: 32.48 (-0.41), IART: 50.26 (-0.15)
Integra LifeSciences Holdings (IART) Shares Cross Below 200 DMA
MarketNewsVideo.com - Tue Nov 04, 3:33PM CST
In trading on Tuesday, shares of Integra LifeSciences Holdings Corp crossed below their 200 day moving average of $47.35, changing hands as low as $47.02 per share. Integra LifeSciences Holdings Corp shares are currently trading off about 8.3% on...
IART: 50.26 (-0.15)
Integra Beats Earnings, Sales Up Y/Y, Outlook Lowered - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 10:20AM CST
Integra's (IART) total revenue during the reported quarter increased 7.7% year over year to $229.7 million, but missed the Zacks Consensus Estimate by 1.4%
AGEN: 3.22 (+0.07), IART: 50.26 (-0.15), AMAG: 40.04 (-0.79), AFFX: 8.94 (-0.36)
Integra LifeSciences Up 7.2% Since SmarTrend Uptrend Call (IART)
Comtex SmarTrend(R) - Tue Nov 04, 9:36AM CST
SmarTrend identified an Uptrend for Integra LifeSciences (NASDAQ:IART) on June 6th, 2014 at $46.21. In approximately 5 months, Integra LifeSciences has returned 7.23% as of today's recent price of $49.54.
IART: 50.26 (-0.15)
Integra LifeSciences Holdings' (IART) CEO Peter Arduini on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 12:06AM CST
IART: 50.26 (-0.15)
Integra LifeSciences Announces Strategic Portfolio Alignment and Plans to Create Stand-Alone Spine Business as a Separate Public Company
GlobeNewswire - Mon Nov 03, 5:28PM CST
-- Plans to Spin Off Spine Business to Create SeaSpine, a New Publicly Traded Company, By Means of Tax-Free Distribution to Integra Shareholders
IART: 50.26 (-0.15)
Integra LifeSciences Reports Third Quarter 2014 Financial Results
GlobeNewswire - Mon Nov 03, 5:28PM CST
Revenue Increased 7.7% to $229.7 Million
IART: 50.26 (-0.15)
Integra LifeSciences Holdings beats by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 3:28PM CST
IART: 50.26 (-0.15)
Integra LifeSciences Holdings (IART) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Nov 03, 3:25PM CST
IART: 50.26 (-0.15)
Germany Tissue Engineered - Skin Substitutes Market Outlook to 2020
M2 - Mon Nov 03, 10:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/w3lrfq/germany_tissue) has announced the addition of the "Germany Tissue Engineered - Skin Substitutes Market Outlook to 2020" report to their offering. "Germany Tissue Engineered - Skin Substitutes Market Outlook to 2020", provides key market data on the Germany Tissue Engineered - Skin Substitutes market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments - Synthetic Skin Substitutes, Biosynthetic Skin Substitutes and Biologic Skin Substitutes (Allograft (Cellular and Acellular) and Xenograft Acellular). The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Tissue Engineered - Skin Substitutes market wherever available. The data in the report is derived from dynamic market forecast models. The publisher uses epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Tissue Engineered - Skin Substitutes Market, Germany 4 Overview of Key Companies in Germany, Tissue Engineered - Skin Substitutes Market 5 Appendix Companies Mentioned - Organogenesis, Inc. - Molnlycke Health Care AB - Smith & Nephew Plc - BSN medical GmbH - MedSkin Solutions Dr. Suwelack AG - Kinetic Concepts, Inc. - Covidien plc - Integra LifeSciences Holdings Corporation For more information visit http://www.researchandmarkets.com/research/w3...any_tissue
SNN: 32.48 (-0.41), IART: 50.26 (-0.15)
Italy Tissue Engineered - Skin Substitutes Market Outlook to 2020: Key players covered include Organogenesis, Smith & Nephew and Molnlycke Health Care
M2 - Wed Dec 10, 11:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/gzsh2g/italy_tissue) has announced the addition of the "Italy Tissue Engineered - Skin Substitutes Market Outlook to 2020" report to their offering. Our new report, "Italy Tissue Engineered - Skin Substitutes Market Outlook to 2020", provides key market data on the Italy Tissue Engineered - Skin Substitutes market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments - Synthetic Skin Substitutes, Biosynthetic Skin Substitutes and Biologic Skin Substitutes (Allograft (Cellular and Acellular) and Xenograft Acellular). The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Tissue Engineered - Skin Substitutes market wherever available. The data in the report is derived from dynamic market forecast models. The publisher uses epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible. The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers. Key Topics Covered: 1 List of Tables 2 Introduction 3 Tissue Engineered - Skin Substitutes Market, Italy 4 Overview of Key Companies in Italy, Tissue Engineered - Skin Substitutes Market 5 Appendix Companies Mentioned: - Organogenesis, Inc. - Molnlycke Health Care AB - Smith & Nephew Plc - BSN medical GmbH - Integra LifeSciences Holdings Corporation - Kinetic Concepts, Inc. - Covidien plc For more information visit http://www.researchandmarkets.com/research/gz...aly_tissue
SNN: 32.48 (-0.41), IART: 50.26 (-0.15)
Asia-Pacific Tissue Engineered - Skin Substitutes Market Outlook to 2020: Key players covered include Japan Tissue Engineering and Smith & Nephew
M2 - Tue Dec 09, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/ctmnfq/asiapacific) has announced the addition of the "Asia-Pacific Tissue Engineered - Skin Substitutes Market Outlook to 2020" report to their offering. Our new report, "Asia-Pacific Tissue Engineered - Skin Substitutes Market Outlook to 2020", provides key market data on the Asia-Pacific Tissue Engineered - Skin Substitutes market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments - Synthetic Skin Substitutes, Biosynthetic Skin Substitutes and Biologic Skin Substitutes (Allograft (Cellular and Acellular) and Xenograft Acellular). The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Tissue Engineered - Skin Substitutes market wherever available. The data in the report is derived from dynamic market forecast models. The publisher uses epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible. Key Topics Covered: 1 List of Tables 2 Introduction 3 Tissue Engineered - Skin Substitutes Market, Asia-Pacific 4 Tissue Engineered - Skin Substitutes Market, Australia 5 Tissue Engineered - Skin Substitutes Market, China 6 Tissue Engineered - Skin Substitutes Market, India 7 Tissue Engineered - Skin Substitutes Market, Japan 8 Tissue Engineered - Skin Substitutes Market, South Korea 9 Overview of Key Companies in Asia-Pacific Tissue Engineered - Skin Substitutes Market 10 Appendix Companies Mentioned: - Japan Tissue Engineering Co., Ltd. - Smith & Nephew Plc - PolyNovo Biomaterials Pty Ltd - Molnlycke Health Care AB - National Tissue Engineering Research Center - L&C Bio - BSN medical GmbH - Covidien plc - Kinetic Concepts, Inc. - CG Bio Inc. - Integra LifeSciences Holdings Corporation - HansBiomed Co., Ltd - Cellumed Co. Ltd For more information visit http://www.researchandmarkets.com/research/ct...siapacific
SNN: 32.48 (-0.41), IART: 50.26 (-0.15)
Symmetry Medical Divests OEM, Surgical Goes Public - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 12:40PM CST
Symmetry Medical Inc. (SMA) recently completed the divestiture of its OEM solutions business unit to Tecomet Inc.
SMA: 9.27 (-0.04), IART: 50.26 (-0.15), MDT: 72.52 (-1.25), CFN: 58.86 (-0.14)
Integra LifeSciences Earnings Review: 14 Days after Announcement Shares Down 7.5% (IART)
Comtex SmarTrend(R) - Mon Nov 17, 3:46PM CST
14 days ago, on November 3rd, 2014, Integra LifeSciences (NASDAQ:IART) reported its earnings. Analysts, on average, expected earnings of $0.74 per share on sales of $233.7 million. Integra LifeSciences actually reported earnings of $0.76 per share on sales of $229.7 million, beating EPS estimates by $0.02 and missing revenue estimates by $3.9 million. Since the company's report, shares of Integra LifeSciences have fallen from $51.49 to $47.64, representing a loss of 7.5% in the past 14 days.
IART: 50.26 (-0.15)
Integra (IART) Strengthens Spinal Implant with Twin Launches - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 2:30PM CST
The latest Interbody and orthobiologic device launches are expected to drive a sequential increase in Integra Lifesciences' (IART) spine sales in the fourth quarter of 2014.
IART: 50.26 (-0.15), ANIP: 54.28 (+2.33), AMAG: 40.04 (-0.79), AFFX: 8.94 (-0.36)
Update: Integra LifeSciences - A Buy After Q3 2014 Earnings
Andy Batts - at Seeking Alpha - Fri Nov 14, 8:23AM CST
IART: 50.26 (-0.15)
Integra LifeSciences wins FDA clearance and controlled market release for Integra Expandable Interbody System in the US
M2 - Fri Nov 14, 6:59AM CST
Medical technology company Integra LifeSciences Holdings (NasdaqGS:IART) said on Thursday that it has received the controlled market release of the Integra Expandable Interbody System in the US.
IART: 50.26 (-0.15)
Integra LifeSciences Announces FDA Clearance and Controlled Market Release of Expandable Interbody System for Spinal Surgery
GlobeNewswire - Thu Nov 13, 7:30AM CST
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the controlled market release of the Integra Expandable Interbody System, in the United States. The system, which received 510(k) clearance from the United States Food and Drug Administration (FDA) earlier this year, is intended for spinal fusion procedures at one or two contiguous levels (L2-S1) in skeletally mature patients with degenerative disc disease (DDD). The device is intended for use with autogenous bone graft and supplemental fixation and can be used in either posterior or transforaminal lumbar interbody fusion procedures. These procedures are performed to help alleviate pain and nerve compression by fusing and stabilizing adjacent vertebrae in the lower back.
IART: 50.26 (-0.15)
North America Tissue Engineered Skin Substitutes Market Outlook to 2020: Key Players Organogenesis, Inc, Kinetic Concepts, Inc., Shire Plc & Smith & Nephew Plc.
M2 - Thu Nov 13, 3:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/8vj74f/north_america) has announced the addition of the "North America Tissue Engineered - Skin Substitutes Market Outlook to 2020" report to their offering. "North America Tissue Engineered - Skin Substitutes Market Outlook to 2020", provides key market data on the North America Tissue Engineered - Skin Substitutes market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments - Synthetic Skin Substitutes, Biosynthetic Skin Substitutes and Biologic Skin Substitutes (Allograft (Cellular and Acellular) and Xenograft Acellular). The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Tissue Engineered - Skin Substitutes market wherever available. The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers. Capital equipment-based forecasting models are done based on the installed base, replacements and new sales of a specific device/equipment in healthcare facilities such as hospitals, clinics and diagnostic centers. Data for average number of units per facility is used to arrive at the installed base of the capital equipment. Sales for a particular year are arrived at by calculating the replacement units and new units (additional and first-time purchases). Scope - Annualized market revenues (USD million), volume (units) and average prices (in US dollars) data for each of the market segments. Data is provided from 2005 to 2013 and forecast to 2020. - 2013 company shares and distribution shares data for Tissue Engineered - Skin Substitutes market. - Global corporate-level profiles of key companies operating within the North America Tissue Engineered - Skin Substitutes. Companies Mentioned - Organogenesis, Inc. - Shire Plc - Kinetic Concepts, Inc. - Integra LifeSciences Holdings Corporation - Smith & Nephew Plc - Covidien plc - Molnlycke Health Care AB - BSN medical GmbH For more information visit http://www.researchandmarkets.com/research/8v...th_america
SNN: 32.48 (-0.41), IART: 50.26 (-0.15), SHPG: 213.70 (-0.41)
Integra LifeSciences Introduces Integra(R) Pocket Strip and Integra(R) Shaped Strip DBM Implants
GlobeNewswire - Wed Nov 12, 7:54AM CST
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the limited market release of a new orthobiologic implant. The Demineralized Bone Matrix (DBM) Strip implant is used primarily for posterior lumbar fusion, a surgical procedure intended to promote bone fusion along the posterior elements of the spine. Integra's newest orthobiologic implant, distributed by Integra's subsidiary IsoTis OrthoBiologics, will be featured at the North American Spine Society (NASS) 29 annual meeting, November 12 - 15, 2014 in San Francisco, California.
IART: 50.26 (-0.15)
BRIC Tissue Engineered - Skin Substitutes Market Outlook to 2020: Key Players are Japan Tissue Engineering Co., Ltd. and Smith & Nephew Plc
M2 - Wed Nov 12, 5:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/scwv2r/bric_tissue) has announced the addition of the "BRIC Tissue Engineered - Skin Substitutes Market Outlook to 2020" report to their offering. The report provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Tissue Engineered - Skin Substitutes market wherever available. The data in the report is derived from dynamic market forecast models. The publisher uses epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible. The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers. Skin Substitutes market. - Synthetic Skin Substitutes - Biosynthetic Skin Substitutes and Biologic - Skin Substitutes (Allograft (Cellular and Acellular) and Xenograft Acellular). Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Tissue Engineered - Skin Substitutes Market, BRIC 4 Tissue Engineered - Skin Substitutes Market, Brazil 5 Tissue Engineered - Skin Substitutes Market, Russia 6 Tissue Engineered - Skin Substitutes Market, India 7 Tissue Engineered - Skin Substitutes Market, China 8 Overview of Key Companies in BRIC Tissue Engineered - Skin Substitutes Market 9 Appendix Companies Mentioned - National Tissue Engineering Research Center - Organogenesis, Inc. - Kinetic Concepts, Inc. - Smith & Nephew Plc - Integra LifeSciences Holdings Corporation - Eucare Pharmaceuticals (P) Ltd. - MedSkin Solutions Dr. Suwelack AG - Molnlycke Health Care AB - BSN medical GmbH - Covidien plc For more information visit http://www.researchandmarkets.com/research/sc...ric_tissue
SNN: 32.48 (-0.41), IART: 50.26 (-0.15)
Integra LifeSciences Holdings (IART) Shares Cross Below 200 DMA
MarketNewsVideo.com - Tue Nov 04, 3:33PM CST
In trading on Tuesday, shares of Integra LifeSciences Holdings Corp crossed below their 200 day moving average of $47.35, changing hands as low as $47.02 per share. Integra LifeSciences Holdings Corp shares are currently trading off about 8.3% on...
IART: 50.26 (-0.15)
Integra Beats Earnings, Sales Up Y/Y, Outlook Lowered - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 10:20AM CST
Integra's (IART) total revenue during the reported quarter increased 7.7% year over year to $229.7 million, but missed the Zacks Consensus Estimate by 1.4%
AGEN: 3.22 (+0.07), IART: 50.26 (-0.15), AMAG: 40.04 (-0.79), AFFX: 8.94 (-0.36)
Integra LifeSciences Up 7.2% Since SmarTrend Uptrend Call (IART)
Comtex SmarTrend(R) - Tue Nov 04, 9:36AM CST
SmarTrend identified an Uptrend for Integra LifeSciences (NASDAQ:IART) on June 6th, 2014 at $46.21. In approximately 5 months, Integra LifeSciences has returned 7.23% as of today's recent price of $49.54.
IART: 50.26 (-0.15)
Integra LifeSciences Holdings' (IART) CEO Peter Arduini on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 12:06AM CST
IART: 50.26 (-0.15)
Integra LifeSciences Announces Strategic Portfolio Alignment and Plans to Create Stand-Alone Spine Business as a Separate Public Company
GlobeNewswire - Mon Nov 03, 5:28PM CST
-- Plans to Spin Off Spine Business to Create SeaSpine, a New Publicly Traded Company, By Means of Tax-Free Distribution to Integra Shareholders
IART: 50.26 (-0.15)
Integra LifeSciences Reports Third Quarter 2014 Financial Results
GlobeNewswire - Mon Nov 03, 5:28PM CST
Revenue Increased 7.7% to $229.7 Million
IART: 50.26 (-0.15)
Integra LifeSciences Holdings beats by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 3:28PM CST
IART: 50.26 (-0.15)
Integra LifeSciences Holdings (IART) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Nov 03, 3:25PM CST
IART: 50.26 (-0.15)
Germany Tissue Engineered - Skin Substitutes Market Outlook to 2020
M2 - Mon Nov 03, 10:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/w3lrfq/germany_tissue) has announced the addition of the "Germany Tissue Engineered - Skin Substitutes Market Outlook to 2020" report to their offering. "Germany Tissue Engineered - Skin Substitutes Market Outlook to 2020", provides key market data on the Germany Tissue Engineered - Skin Substitutes market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments - Synthetic Skin Substitutes, Biosynthetic Skin Substitutes and Biologic Skin Substitutes (Allograft (Cellular and Acellular) and Xenograft Acellular). The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Tissue Engineered - Skin Substitutes market wherever available. The data in the report is derived from dynamic market forecast models. The publisher uses epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Tissue Engineered - Skin Substitutes Market, Germany 4 Overview of Key Companies in Germany, Tissue Engineered - Skin Substitutes Market 5 Appendix Companies Mentioned - Organogenesis, Inc. - Molnlycke Health Care AB - Smith & Nephew Plc - BSN medical GmbH - MedSkin Solutions Dr. Suwelack AG - Kinetic Concepts, Inc. - Covidien plc - Integra LifeSciences Holdings Corporation For more information visit http://www.researchandmarkets.com/research/w3...any_tissue
SNN: 32.48 (-0.41), IART: 50.26 (-0.15)
